Claims for Patent: 7,713,524

Summary for Patent: 7,713,524

Title:	Use of ADCC-optimized antibodies for treating low-responder patients
Abstract:	The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Inventor(s):	Bourel; Dominique (La Madeleine, FR), Jorieux; Sylvie (Villeneuve d\'Ascq, FR), Romeuf; Christophe De (Lambersart, FR), Klein; Philippe (Lille, FR), Gaucher; Christine (Sequedin, FR), Bihoreau; Nicolas (Orsay, FR), Nony; Emmanuel (Antony, FR)
Assignee:	Laboratoire Francais du Fractionnement et des Biotechnologies (Les Ulis, FR)
Application Number:	10/566,358
Patent Claims:	1. A method for treating haemolytic disease of the newborn, Sezary Syndrome, chronic myeloid leukaemias, chronic lymphoid leukaemias (CLL-B), cancer, breast cancer, conditions related to the environment, infectious diseases, chronic fatigue syndrome (CFS), parasitic infections, or viral infections, comprising administering a composition of antibodies specific to the condition to be treated, wherein said antibodies are over 60%, for the forms G0+G1+G0F+G1F, given that the forms G0F+G1F are lower than 50%, to patients homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or patients heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F). 2. The method according to claim 1, wherein the dose of said antibody administered to the patient is 50 times lower than a dose of an antibody of the same specificity but of different glycosylation or produced in a CHO line. 3. The method according to claim 1, wherein that the antibody is directed against a non-ubiquitous antigen present in healthy donor cells, or an antigen of a pathological cell or of an organism pathogenic for humans. 4. The method according to claim 1 for treating cancers of positive HLA class-II cells, B-cell lymphomas, acute B-cell leukaemias, Burkitt's syndrome, Hodgkin's lymphoma, myeloid leukaemias, chronic B-cell lymphoid leukaemias (CLL-B), non-Hodgkin's T-cell leukaemias and lymphomas and chronic myeloid leukaemias. 5. The method according to claim 1, wherein the antibody is anti-HLA-DR. 6. The method according to claim 1, wherein the antibody is anti-CD20. 7. The method according to claim 3, wherein the antibody is selected from the group consisting of anti-HLA-DR, anti-CD20, anti Ep-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, anti-CD44, and anti-viral antibodies. 8. The method according to claim 1, wherein the antibody is selected from the group consisting of anti-HLA-DR, anti-CD20, anti EP-CAM, anti HER2, anti CD52, anti HER1, anti GD3, anti CA125, anti GD, anti GD2, anti CD-23 and anti Protein C, anti-KIR3DL2, anti-EGFR, anti-CD25, anti-CD38, anti-CD30, anti-CD33, anti-CD44, and anti-viral antibodies. 9. A method for treating a condition, comprising administering a composition of antibodies to patients homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or patients heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F) wherein said antibodies are over 60%, for the forms G0+G1+G0F+G1F, given that the forms G0F+G1F are lower than 50%, and wherein the condition and the antibodies are selected from: colorectal cancer and anti Ep-CAM antibody; B cell lymphoma thrombocytopeni a purpura and anti-CD20 antibody; ovarian cancer and anti-HER2 antibody; RSV and palivizumab antibody; leukaemia and anti-CD52 antibody; NHL and anti-CD20 antibody; cancer and anti-HER1 antibody; lung, colorectal, and kidney cancers and anti VEGF antibody; non-Hodgkin's lymphoma and anti-CD22 antibody; breast, ovarian, prostate cancers and bispecific HER2Neu/CD64 antibody; small cell lung carcinoma and anti-GD3 antibody; ovarian cancer and anti-CA125 antibody; malignant melanoma and anti-GD antibody; cancers and EGF antibody; cancers and anti-GD2 antibody; and prostate cancer and anti-PSMA. 10. A method for increasing the ADCC activity of an antibody in a patient, comprising administering to said patient a composition of antibodies, wherein said antibodies are over 60%, for the forms G0+G1+G0F+G1F, given that the forms G0F+G1F are lower than 50%, and wherein said patient is homozygous for phenylalanine in position 158 of CD16 (FCGR3A-158F homozygotes) or said patient is heterozygous for valine/pheynylalanine in position 158 of CD16 (FCGR3A-158V/F).

Details for Patent 7,713,524

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2023-07-31
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2023-07-31